Abstract: The present disclosure provides a method for identifying a genomic aberration in one or more biological samples of a subject. The biological samples may be obtained and may comprise a nucleic acid sample that has or is suspected of having one or more genomic aberration(s) that appears at a frequency of less than about 5% in the nucleic acid sample. The nucleic acid sample may be enriched for a plurality of nucleic acid sequences to provide an enriched nucleic acid sample using a probe set comprising probes that have an on-target rate as a group of at least about 80%. Next, the enriched nucleic acid sample may be sequenced to generate sequencing reads. The sequencing reads can be processed to identify genomic aberration(s) in the one or more biological samples of the subject that appears at a frequency of less than about 5% in the nucleic acid sample.

Abstract: The present disclosure provides a method for qualifying a subject for a subset of therapies. The medical history data and biologic data may be received for the subject wherein the biologic data is generated from one or more biological samples of the subject. Then, the medical history data and the biologic data may be computer analyzed to yield a genomic-based medical history analysis for the subject. The genomic-based medical history analysis may be used for the subject to query one or more databases of therapies for the subject, to generate the subset of therapies for which the subject qualifies.

Abstract: Provided herein are compositions and methods for predicting whether a subject with cancer will be responsive to treatment with an EGFR TKI and for the treatment of cancer in a subject.